Budapest, Hungary

Katain Budainee Simonyi

This inventor holds 1 USPTO granted patent. Top assignee: Egis Gyogyszergyar. Active years: 1990.


% Patents Active = 100.0

Average Co-Inventor Count = 10.0

ph-index = 1

Forward Citations = 26(Granted Patents)


Company Filing History:


Years Active: 1990

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Katain Budainee Simonyi: Innovator in Pharmaceutical Chemistry

Introduction

Katain Budainee Simonyi is a notable inventor based in Budapest, Hungary. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of tranquilizers. His work has led to the creation of innovative compounds that have potential therapeutic applications.

Latest Patents

Simonyi holds a patent for "Thiazolo/4,5-c/quinolines as major tranquilizers." This invention relates to new thiazolo[4,5-c]quinoline derivatives of the general Formula I and acid addition salts thereof. The patent outlines a process for the preparation of these compounds and pharmaceutical compositions that include them. His innovative approach in this area has the potential to enhance treatment options for patients requiring tranquilizers.

Career Highlights

Simonyi is associated with Egis Gyogyszergyar, a prominent pharmaceutical company in Hungary. His work at Egis has allowed him to focus on research and development in the pharmaceutical sector. With a patent portfolio that includes 1 patent, he has established himself as a key figure in the industry.

Collaborations

Throughout his career, Simonyi has collaborated with talented individuals such as Zsuzsa Furts and Julia Timar. These collaborations have fostered a creative environment that encourages innovation and the development of new pharmaceutical solutions.

Conclusion

Katain Budainee Simonyi's contributions to pharmaceutical chemistry exemplify the impact of innovative thinking in medicine. His work continues to influence the development of new tranquilizers, showcasing the importance of research and collaboration in advancing healthcare solutions.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…